Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme.

作者: Mark A. Rosenthal , Michael L. Gruber , Jon Glass , Anita Nirenberg , Jonathan Finlay

DOI: 10.1023/A:1006426215005

关键词:

摘要: Taxol has activity in the treatment of high grade gliomas but estramustine phosphate (EMP) not been used this setting. In vitro data demonstrates that EMP is cytotoxic to glioma cell lines and binding proteins are expressed by cells. The combination reported be active hormone-refractory prostate cancer taxane-resistant breast ovarian cancer. We therefore performed a phase II study assess toxicity gliomas. was given at dose 225 mg/m2 intravenously over three hours on day 1 900 orally days through 3. Cycles were repeated every weeks. Twenty patients with recurrent glioblastoma multiforme (GBM) enrolled: 11 male, median age 45 years. All received anti-epileptic medications 17 (80%) had prior chemotherapy. Of 18 evaluable patients, two partial responses (11) six stable disease (33%) for minimum eight Treatment well tolerated 3 neutropenia occurring only patients. There no other or 4 toxicities. time progression cohort weeks (range 3-60+ weeks). overall survival 12 conclusion, modest GBM.

参考文章(18)
Solveig Eklov, Sten Nilsson, Kenneth Wester, Christer Busch, Ensaf Mahdy, Per Bjork, Per-Uno Malmstrom, Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest. Anticancer Research. ,vol. 16, pp. 1819- 1822 ,(1996)
R. Henriksson, E. Von Schoultz, J. Bergh, P. Björk, A. T. Bergenheim, H. Svedberg, Estramustine-Binding Protein and Specific Binding of the Anti-Mitotic Compound Estramustine in Astrocytoma Cancer Research. ,vol. 54, pp. 4974- 4979 ,(1994)
Eric T. Wong, Kenneth R. Hess, Mary Jo Gleason, Kurt A. Jaeckle, Athanassios P. Kyritsis, Michael D. Prados, Victor A. Levin, W.K. Alfred Yung, Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials Journal of Clinical Oncology. ,vol. 17, pp. 2572- 2578 ,(1999) , 10.1200/JCO.1999.17.8.2572
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277
Mitchell A. Cahan, Kevin A. Walter, O. Michael Colvin, Henry Brem, Cytotoxicity of taxol in vitro against human and rat malignant brain tumors Cancer Chemotherapy and Pharmacology. ,vol. 33, pp. 441- 444 ,(1994) , 10.1007/BF00686276
Charles D. Smith, Jack T. Zilfou, Xinqun Zhang, Gary R. Hudes, Kenneth D. Tew, Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins Cancer. ,vol. 75, pp. 2597- 2604 ,(1995) , 10.1002/1097-0142(19950515)75:10<2597::AID-CNCR2820751030>3.0.CO;2-R
Kenneth J. Pienta, Harmesh Naik, Jeffrey E. Lehr, Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo. Urology. ,vol. 48, pp. 164- 170 ,(1996) , 10.1016/S0090-4295(96)00109-4
Eric Burton, Michael Prados, New chemotherapy options for the treatment of malignant gliomas Current Opinion in Oncology. ,vol. 11, pp. 157- 161 ,(1999) , 10.1097/00001622-199905000-00003
Joseph M. Piepmeier, David L. Keefe, Marc A. Weinstein, Daizo Yoshida, Jan Zielinski, Ted T. Lin, Zhaochon Chen, Frederick Naftolin, Estramustine and Estrone Analogs Rapidly and Reversibly Inhibit Deoxyribonucleic Acid Synthesis and Alter Morphology in Cultured Human Glioblastoma Cells Neurosurgery. ,vol. 32, pp. 422- 431 ,(1993) , 10.1227/00006123-199303000-00014